David Hipkiss | Chief Executive Officer
Enesi Pharma Limited | United Kingdom

David Hipkiss, Chief Executive Officer, Enesi Pharma Limited

David joined Enesi Pharma in September 2017 as CEO. Prior to Enesi, he was Chief Business Officer of Circassia Pharmaceuticals, and a member of its Senior Management Team with global group responsibility for all M&A, partnering and licensing activities.
Before joining Circassia, David was CEO and co-founder of Prosonix, a particle engineering-enabled respiratory product company, taking it from its establishment in 2006, raising more than £25 million from leading international life sciences investors and institutions over several financing rounds, through to its successful sale in 2015 to Circassia for £100 million.
He has more than 25 years of business development and licensing experience concerning cutting-edge technologies in high growth, complex, IP-rich environments, with a prime focus on the pharmaceutical industry.  He has also held a number of positions with increasing seniority at Air Products, Chiroscience /ChiroTech Technology Ltd, Ascot plc, Dow Pharma, and Accentus.
David holds a degree in Chemical Engineering from the University of Birmingham, UK

Appearances:



DC Co-conference Day 2 April 4 @ 10:25

Technology showcase 4

ImplaVaxTM – Unique needle free solid dose vaccine platform delivering enhanced immunogenicity with ultimate convenience and no cold chain
 

back to speakers